Your browser is no longer supported. Please, upgrade your browser.
Settings
BIVV Bioverativ Inc. daily Stock Chart
BIVV [NASD]
Bioverativ Inc.
Index- P/E38.14 EPS (ttm)2.74 Insider Own0.20% Shs Outstand108.13M Perf Week0.75%
Market Cap11.28B Forward P/E22.25 EPS next Y4.69 Insider Trans0.00% Shs Float107.93M Perf Month1.11%
Income296.80M PEG1.80 EPS next Q1.01 Inst Own99.15% Short Float2.13% Perf Quarter105.48%
Sales1.17B P/S9.65 EPS this Y-32.80% Inst Trans3.59% Short Ratio1.05 Perf Half Y85.13%
Book/sh8.30 P/B12.57 EPS next Y12.96% ROA27.20% Target Price91.22 Perf Year118.38%
Cash/sh4.04 P/C25.84 EPS next 5Y21.22% ROE49.00% 52W Range48.14 - 104.43 Perf YTD93.43%
Dividend- P/FCF19.09 EPS past 5Y- ROI32.50% 52W High0.21% Beta-
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin76.10% 52W Low117.39% ATR1.77
Employees460 Current Ratio2.00 Sales Q/Q28.30% Oper. Margin38.30% RSI (14)89.80 Volatility0.47% 0.54%
OptionableYes Debt/Eq0.00 EPS Q/Q-64.20% Profit Margin30.40% Rel Volume1.46 Prev Close104.30
ShortableYes LT Debt/Eq0.00 EarningsFeb 13 AMC Payout0.00% Avg Volume2.19M Price104.65
Recom2.90 SMA201.15% SMA5033.96% SMA20067.92% Volume752,525 Change0.34%
Jan-24-18Downgrade Argus Buy → Hold
Jan-23-18Upgrade Morgan Stanley Underweight → Equal-Weight
Jan-18-18Resumed Credit Suisse Neutral $65
Oct-23-17Resumed Piper Jaffray Overweight $71
Sep-20-17Upgrade Argus Hold → Buy $64
Sep-15-17Initiated RBC Capital Mkts Sector Perform $59
Aug-17-17Initiated Evercore ISI In-line $58
Jun-30-17Resumed Jefferies Buy
Jun-28-17Initiated William Blair Mkt Perform
Jun-23-17Initiated Deutsche Bank Hold $65
May-24-17Upgrade Credit Suisse Underperform → Neutral
Apr-24-17Downgrade Gabelli & Co Buy → Hold
Mar-31-17Initiated Argus Hold $51
Mar-27-17Reiterated Stifel Buy $54 → $57
Mar-16-17Initiated Credit Suisse Underperform
Mar-13-17Downgrade Goldman Buy → Neutral
Feb-28-17Upgrade Piper Jaffray Neutral → Overweight $44 → $65
Feb-15-17Initiated Leerink Partners Outperform $56
Feb-07-17Initiated Raymond James Strong Buy $59
Feb-06-17Initiated Piper Jaffray Neutral
Feb-22-18 07:40AM  Wired News Voyager Therapeutics Signs Global Collaboration Agreement with AbbVie to Develop New Treatments for Tau-Related Neuro-Degenerative Diseases ACCESSWIRE
Feb-14-18 09:48PM  Bioverativ Inc (BIVV) Files 10-K for the Fiscal Year Ended on December 31, 2017 GuruFocus.com
07:00AM  Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A Business Wire
Feb-13-18 04:15PM  Bioverativ Reports Fourth Quarter and Full Year 2017 Performance Business Wire
10:04AM  [$$] 3 Biotechs That Could Benefit From an M&A Frenzy Barrons.com
Feb-08-18 01:02PM  ACT NOW: Monteverde & Associates PC Announces an Investigation of Bioverativ Inc. - BIVV ACCESSWIRE
05:56AM  Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc. GlobeNewswire
Feb-07-18 03:53AM  Drugmaker Sanofi sees return to profit growth this year Reuters
Feb-05-18 04:30PM  Biotech, Pharma Stocks Tumble Amid Big Market Sell-Off TheStreet.com
Feb-01-18 03:00PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Into Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders - BIVV ACCESSWIRE
Jan-31-18 12:53PM  Biogen Spin-Off Bioverativ To Be Acquired Forbes
Jan-29-18 08:07PM  Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom Reuters
10:20AM  Sanofi beats Novo to buy Ablynx for 3.9 billion euros in biotech M&A boom Reuters
Jan-24-18 02:32PM  The Law Offices of Vincent Wong Notifies Investors of an Investigation of Bioverativ Inc. in Connection with the Sale of the Company to Sanofi Business Wire
01:26PM  Why Investors Should Stay Long Eli Lilly and Co Stock InvestorPlace
12:39PM  WeissLaw LLP Investigates Bioverativ Inc. Acquisition PR Newswire
11:40AM  Argus: Bioverativ Shares Fully Valued After Sanofi Buyout Offer Benzinga
09:00AM  Will Sanofi's Big Hemophilia Deal Pay Off? Motley Fool
04:42AM  Genzyme Corporation -- Moody's affirms Sanofi's A1 ratings following Bioverativ acquisition Moody's
Jan-23-18 12:30PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Bioverativ Inc. Buyout Business Wire
09:00AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders Business Wire
Jan-22-18 03:57PM  SHAREHOLDER ALERT: Monteverde & Associates PC Launches An Investigation of the Board of Directors and Officers of Bioverativ, Inc. - BIVV PR Newswire +61.89%
12:19PM  ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Bioverativ Inc. PR Newswire
12:08PM  Dealmaking drives European stocks as equity melt-up continues Reuters
11:45AM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
11:43AM  Is Sanofis Bioverative Inc Buyout Just the Start? InvestorPlace
11:23AM  Biotech M&A takes off as Sanofi and Celgene spend $20 billion Reuters
10:48AM  New drugs recast $10 billion haemophilia market as Sanofi swoops in Reuters
10:44AM  BIOVERATIV INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout Business Wire
10:21AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Bioverativ Inc. to Sanofi for $105 Per Share is Fair to Shareholders BIVV Business Wire
09:42AM  Biotech ETF rallies on merger news, on track for highest close since 2015 MarketWatch
08:49AM  Johnson Fistel, Announces Investigations of the Proposed Sales of Bioverativ Inc., and Juno Therapeutics, Inc. PR Newswire
08:00AM  Why Bioverativ Inc. Stock Is Soaring Today Motley Fool
08:00AM  The Government Shutdown May Actually Be a Positive for the Stock Market TheStreet.com
05:43AM  Bioverativ Inc Stock Gets 64% Premium in Acquisition by Sanofi InvestorPlace
01:25AM  Sanofi confirms deal to buy Bioverativ for $11.6 billion Reuters
01:03AM  Sanofi to Acquire Bioverativ for $11.6 Billion GlobeNewswire
Jan-17-18 01:15PM  4 Great Healthcare Stocks to Buy Ahead of Q4 Earnings InvestorPlace
Jan-16-18 04:15PM  Bioverativ to Report Fourth Quarter and Year-End 2017 Financial Results on February 13, 2018 Business Wire
Jan-12-18 12:40PM  Biotech Stocks Near Massive Breakout Investopedia
Jan-02-18 04:15PM  Bioverativ to Present at the 2018 J.P. Morgan Healthcare Conference Business Wire
Dec-27-17 11:02AM  ETFs with exposure to Bioverativ, Inc. : December 27, 2017 Capital Cube
Dec-22-17 04:05PM  Bioverativ Announces 2018 Annual Meeting of Stockholders Business Wire
Dec-14-17 12:57PM  ETFs with exposure to Bioverativ, Inc. : December 14, 2017 Capital Cube
Dec-11-17 02:47PM  Bioverativs Investigational BIVV009 Demonstrates Safety, Tolerability and Efficacy in Phase 1b Clinical Trial in Cold Agglutinin Disease (CAgD) Patients Business Wire
10:02AM  New Data Show Extended Prophylactic Dosing with ALPROLIX® Provides Safe and Effective Protection in People with Severe Hemophilia B Business Wire
Dec-10-17 09:02AM  Study Shows Weekly Prophylactic Treatment with ELOCTATE® Resulted in Bleed Protection and Target Joint Resolution in People with Hemophilia A Business Wire
Dec-09-17 09:02AM  ALPROLIX® Demonstrates Higher Tissue Distribution and Retention in Joints Compared to Other Factor IX Molecules in a Preclinical Imaging Study Business Wire
Dec-04-17 10:54AM  ETFs with exposure to Bioverativ, Inc. : December 4, 2017 Capital Cube
Nov-27-17 07:30AM  U.S. Label Update for ALPROLIX® Adds Data Reinforcing Efficacy and Safety of Long-Term Prophylactic Treatment in Adults, Adolescents and Children with Hemophilia B Business Wire
Nov-24-17 10:26AM  ETFs with exposure to Bioverativ, Inc. : November 24, 2017 Capital Cube
Nov-21-17 04:15PM  Bioverativ to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference Business Wire
Nov-13-17 11:52AM  ETFs with exposure to Bioverativ, Inc. : November 13, 2017 Capital Cube
Nov-08-17 08:10AM  Detailed Research: Economic Perspectives on Wayfair, Allison Transmission, Paychex, Bioverativ, Diamond Offshore, and Stryker What Drives Growth in Today's Competitive Landscape GlobeNewswire
Nov-02-17 11:54AM  ETFs with exposure to Bioverativ, Inc. : November 2, 2017 Capital Cube
Nov-01-17 04:00PM  Bioverativ to Present at the Credit Suisse 2017 Healthcare Conference Business Wire
09:40AM  Bioverativ to Present New Data on Rare Blood Disorder Programs at ASH 2017 Annual Meeting Business Wire
09:35AM  Bioverativ, Inc. :BIVV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017 Capital Cube
Oct-31-17 08:00AM  Interim Data Published in Haemophilia Show Improvements in Long-Term Joint Health for Hemophilia A Patients Following Prophylactic Treatment with ELOCTATE® Business Wire
Oct-26-17 04:15PM  Bioverativ Reports Third Quarter 2017 Performance Business Wire
Oct-23-17 10:24AM  ETFs with exposure to Bioverativ, Inc. : October 23, 2017 Capital Cube
Oct-09-17 11:19AM  ETFs with exposure to Bioverativ, Inc. : October 9, 2017 Capital Cube
Oct-03-17 08:17AM  Bioverativ, Inc. breached its 50 day moving average in a Bullish Manner : BIVV-US : October 3, 2017 Capital Cube
Oct-02-17 05:30PM  Small Caps, Dow Names Lead; Should You Buy These 5 Stocks In Bases? Investor's Business Daily
07:30AM  Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia PR Newswire
Sep-28-17 10:30AM  Bioverativ to Report Third Quarter 2017 Financial Results on October 26, 2017 Business Wire
10:10AM  ETFs with exposure to Bioverativ, Inc. : September 28, 2017 Capital Cube
Sep-27-17 09:02AM  Bioverativ, Inc. :BIVV-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017 Capital Cube
Sep-20-17 10:51AM  Biogen Spinoff Bioverativ Is A Buy Benzinga
Sep-06-17 09:07AM  Inside Bioverativs 1H17 Performance Market Realist
02:00AM  Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Hemophilia and Sickle Cell Disease Business Wire
02:00AM  Bioverativ and Bicycle Therapeutics Enter into Strategic Research Collaboration to Develop Therapies for Haemophilia and Sickle Cell Disease Business Wire
Aug-30-17 05:00PM  Bioverativ to Present at Citis 12th Biotech Conference Business Wire
Aug-24-17 07:30AM  Bioverativ and Invicro Form Novel, Advanced Imaging Collaboration Focused on Improving Management of Joint Health in People with Hemophilia Business Wire
Aug-18-17 07:16PM  Bioverativ, Inc. Value Analysis (NASDAQ:BIVV) : August 18, 2017 Capital Cube
Aug-07-17 09:28AM  Bioverativ, Inc. breached its 50 day moving average in a Bearish Manner : BIVV-US : August 7, 2017 Capital Cube
Aug-03-17 10:16AM  Stocks Drop But Tesla Races Higher, Dow Giant Is In Buy Zone Investor's Business Daily
05:02AM  Bioverativ Up On Earnings Investor's Business Daily
Aug-02-17 04:31PM  Bioverativ Reports Second Quarter 2017 Performance Business Wire
Jul-28-17 01:35PM  Bioverativ Expected to Report Robust Revenue Growth in 2017 Market Realist
10:33AM  Analyst Recommendations for Bioverativ in July 2017 Market Realist
Jul-25-17 12:35PM  Biotech Movers: Novavax Falls Again After New Data on RSV Vaccine Fails to Excite TheStreet.com
07:11AM  Biogen stock surges nearly 6% on Q2 profit, revenue beats MarketWatch
Jul-10-17 05:02PM  Could Biogen Spinoff Bioverativ Have A Blockbuster On Its Hands? Investor's Business Daily
02:54PM  Cowen Upgrades Bioverativ Shares To Outperform As TNT009 Heats Up Benzinga
Jul-07-17 07:00AM  Bioverativ to Report Second Quarter 2017 Financial Results on August 2, 2017 Business Wire
Jul-06-17 07:05AM  New Data to be Presented at ISTH Underscore Bioverativs Commitment to Advance Hemophilia Care Business Wire
07:00AM  Bioverativ and Sobi Highlight Commitment to Improving Care for People with Hemophilia at ISTH 2017 Congress Business Wire
Jul-05-17 08:03AM  3 Reasons Sizzling-Hot Bioverativ Stock Can Go Even Higher Motley Fool
Jun-28-17 04:00PM  Bioverativ Completes Acquisition of True North Therapeutics Business Wire
Jun-23-17 08:52PM  How President Trump Has Sent Biotech Stocks Soaring TheStreet.com
Jun-22-17 04:27PM  After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next Investor's Business Daily
02:47PM  Which Stocks Are Showing Rising Relative Strength? Investor's Business Daily
Jun-20-17 01:26PM  Biotech Stocks To Watch And Pharma Industry News Investor's Business Daily
11:31AM  Biotech Stock With 50% Profit Margin Nears Buy Zone Investor's Business Daily
10:31AM  New Strong Sell Stocks for June 20th Zacks
Jun-16-17 09:30AM  Kennametal, Bioverativ and Apple highlighted as Zacks Bull and Bear of the Day Zacks
Jun-15-17 01:16PM  ETFs with exposure to Bioverativ, Inc. : June 15, 2017 Capital Cube
Jun-14-17 07:00AM  Bioverativ announces FDA acceptance of Investigational New Drug Application for BIVV001, a novel, long-acting FVIII hemophilia therapeutic utilizing Amunix XTEN® half-life extension technology GlobeNewswire
Jun-13-17 11:16PM  IPO Stock News And Analysis: Find Today's Top New Issues Investor's Business Daily +5.45%
Bioverativ Inc is a biotechnology company. It is engaged in the discovery, development and commercialization of therapies for the treatment of hemophilia and other blood disorders.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greene JohnEVP, CFO and TreasurerFeb 14Option Exercise0.007,11407,614Feb 15 05:24 PM
Duvall DianthaChief Accounting OfficerFeb 14Option Exercise0.001,39003,518Feb 15 05:11 PM
Vivaldi Coelho RogerioEVP, Chief Global TherapeuticsFeb 14Option Exercise0.007,11407,429Feb 15 05:09 PM
Brudnick RichardEVP, Business DevelopmentFeb 14Option Exercise0.003,744026,432Feb 15 05:06 PM
Cox JohnChief Executive OfficerFeb 14Option Exercise0.0024,3390215,680Feb 15 05:04 PM
Celona LuciaEVP, HR & Corp Commun. OfficerFeb 14Option Exercise0.003,744022,781Feb 15 05:02 PM
DiFabio AndreaEVP, Chief Legal OfficerFeb 14Option Exercise0.003,744034,475Feb 15 04:59 PM
Cox JohnChief Executive OfficerFeb 11Option Exercise9.5318,381175,171199,013Feb 13 05:01 PM